AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
February 26, 2024 12:32 ET
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS ISSUED A NOTICE OF NON-COMPLIANCE-WITHDRAWAL (NON/w) FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AB SCIENCE INTENDS TO SUBMIT A REQUEST...
OrphAI Therapeutics receives Orphan Drug Designation for AIT-101 as a treatment for amyotrophic lateral sclerosis in the European Union
February 15, 2024 10:38 ET
|
OrphAI Therapeutics Inc.
GUILFORD, Conn., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today...
Brooke Eby, ALS Patient and Advocate, to deliver Keynote Address at 2024 MDA Clinical & Scientific Conference
February 15, 2024 09:00 ET
|
Muscular Dystrophy Association
New York, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Brooke Eby will be the keynote speaker at the 2024 MDA Clinical & Scientific...
AB Science fait le point sur la demande d’autorisation de mise sur le marché du masitinib dans la sclérose latérale amyotrophique auprès de l’Agence Européenne des Médicaments
January 26, 2024 12:01 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LA DEMANDE D'AUTORISATION DE MISE SUR LE MARCHÉ DU MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE AUPRÈS DE L'AGENCE EUROPÉENNE DES...
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
January 26, 2024 12:01 ET
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES AN UPDATE IN THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AT THE EUROPEAN MEDICINES AGENCY A DECISION FROM THE EUROPEAN...
OrphAI Therapeutics Announces Oral Presentation and Posters at the 22nd Annual NEALS Conference
October 02, 2023 11:38 ET
|
OrphAI Therapeutics Inc.
GUILFORD, Conn., Oct. 02, 2023 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today data...
AI Therapeutics Announces Name Change to OrphAI Therapeutics
September 28, 2023 11:38 ET
|
AI Therapeutics, Inc.
GUILFORD, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today that it has...
PathMaker Neurosystems Announces Initiation of First-in-Human Trial in ALS for Non-Invasive Neuromodulation Device
September 14, 2023 06:00 ET
|
PathMaker Neurosystems Inc.
BOSTON and PARIS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the...
Global Amyotrophic Lateral Sclerosis Market Size to Reach USD 1,034.7 Million in 2032 | Emergen Research
August 29, 2023 08:56 ET
|
Emergen Research
Vancouver, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The worldwide market for amyotrophic lateral sclerosis achieved a size of USD 613.0 million in the year 2022. According to the most recent study...
Amyotrophic Lateral Sclerosis Treatment Market to Surpass 138.58 Million by 2030 Drives Due to the Availability of Improved Healthcare Expenditure
July 27, 2023 09:15 ET
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford USA, July 27, 2023 (GLOBE NEWSWIRE) -- According to SkyQuest, the rise in the prevalence of amyotrophic lateral sclerosis treatment market has driven a surge in demand for effective...